Evidence map›Paper›PMID 25524722›Full record

ReviewCold Spring Harbor perspectives in medicine2014

Baseball bats and chocolate chip cookies: the judicial treatment of DNA in the myriad genetics litigation.

Ian Binnie, Vanessa Park-Thompson

Open access · hybridAbstract readReview
In one paragraph

Review in Cold Spring Harbor perspectives in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ian BinnieLenczner Slaght Royce Smith Griffin, Toronto, Ontario M5H 3P5, Canada.
Vanessa Park-ThompsonLenczner Slaght Royce Smith Griffin, Toronto, Ontario M5H 3P5, Canada.

Funding

Wellcome Trust
6 · The paper itself

Abstract

In June 2013, the U.S. Supreme Court rendered a controversial ruling that naturally occurring DNA segments are "products of nature" and therefore not patentable subject matter. At this intersection between science and law, in litigation of crucial importance to patients, science, and multibillion-dollar biotech enterprises, the appellate judges sidestepped genetics and engaged in a war of metaphors from diamonds to chocolate chip cookies. This case is not an outlier. Apprehensive judges and juries in both Canada and the United States find many convenient excuses to avoid coming to grips with the underlying science in patent cases. But this is simply not acceptable. Legal rulings must be, and must seem to be, well grounded, as a matter of both law and science. The legitimacy of court decisions in the eyes of the stakeholders and the broader public depends on it.

Indexed as

DNAPatents as TopicBiological ProductsBiotechnologyBRCA2 ProteinGeneticsGenome, HumanHumansInventionsJurisprudencePublic OpinionSupreme Court DecisionsUbiquitin-Protein LigasesUnited StatesBiological ProductsBRAP protein, humanBRCA2 ProteinBRCA2 protein, humanDNAUbiquitin-Protein Ligases

Identifiers

PMID25524722
PMCPMC4448704
OpenAlexW2150706099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.